News & media

September 15, 2021
Casma Therapeutics to Present at the UBS Virtual Biotechnology Private Company Symposium

CAMBRIDGE, Mass., September 15, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer of Casma, will participate in the upcoming virtual UBS Virtual Biotechnology Private Company Symposium being held on September 22-23, 2021.   UBS Virtual Biotechnology Private Company […]

October 4, 2021
Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design new medicines, today announced the publication of new research findings in Science Advances co-authored by Casma scientists, along with Oliver Florey, Ph.D., of the Brabraham Institute, and Casma scientific co-founder Andrea Ballabio, M.D., of the Telethon Institute […]

November 10, 2021
Casma Therapeutics to Present at 2021 Stifel Virtual Healthcare Conference

CAMBRIDGE, Mass., November 10, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the power of autophagy to design innovative new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present at the upcoming Stifel Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10 a.m. ET.   About Casma Therapeutics Casma Therapeutics is harnessing […]

April 7, 2022
Casma Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 7, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma management will participate in virtual investor meetings on April 14, 2022 at the upcoming 21st Annual Needham Virtual Healthcare Conference being held on Monday, April 11 – Thursday, April 14, 2022.   About […]

Investors and Media, George Washington | May 3, 2018
Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies

Company is focusing on lysosomal storage disorders, liver and muscle diseases, inflammation and neurodegeneration CAMBRIDGE, Mass., May 3, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, launched today with $58.5 million in Series A funding from Third Rock Ventures. Casma is pioneering novel strategies […]

Investors and Media | May 30, 2018
Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication

CAMBRIDGE, Mass., May 30, 2018 — Casma Therapeutics Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, today announced the publication of a landmark paper by scientific co-founder Beth Levine describing the health and lifespan benefits of increased autophagy in a mouse model. The study, published in Nature, describes observations […]

Page 3 of 3